PaxMedica, Inc. (PXMD)

NASDAQ: PXMD · IEX Real-Time Price · USD
3.62
+0.27 (8.06%)
At close: Feb 7, 2023, 4:00 PM
3.67
+0.05 (1.38%)
After-hours: Feb 7, 2023, 7:55 PM EST
8.06%
Market Cap 43.57M
Revenue (ttm) n/a
Net Income (ttm) -3.35M
Shares Out 12.04M
EPS (ttm) 0.12
PE Ratio 30.17
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 721,688
Open 3.27
Previous Close 3.35
Day's Range 3.21 - 3.69
52-Week Range 1.36 - 10.48
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Dec 30, 2022

About PXMD

PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomiasis. It is also involved in developing PAX-102, an intranasal formulation of suramin for neurologic... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Aug 26, 2022
Employees 2
Stock Exchange NASDAQ
Ticker Symbol PXMD
Full Company Profile

Financial Performance

Financial Statements

News

Why Is PaxMedica (PXMD) Stock Up Today?

What caused a pop-and-drop in PaxMedica (NASDAQ: PXMD) stock today? PaxMedica is in the headlines due to an arrangement that will reportedly generate over $3 million for the company.

4 days ago - InvestorPlace

PaxMedica, Inc. Secures $3.2 Million Growth Capital From Lind Partners

Additional Capital Will Help Fund Development of PAX-101

4 days ago - GlobeNewsWire

Short Squeeze Stocks: 5 Stocks Wall Street Really DOESN'T Want to Win

Retail investors have taken a particular interest in potential short-squeeze stocks ever since the onset of the coronavirus pandemic. At that time, meme stock favorite GameStop (NYSE: GME) squeezed t...

Other symbols: GROMSI
1 week ago - InvestorPlace

Top 5 most-shorted stocks as of January 2023

The macroeconomic climate in 2022 and 2023 has had a negative impact on many equity investments. Fears of a possible recession and a gloomy attitude among investors have affected companies in precario...

Other symbols: CVNAGROMSISTR
2 weeks ago - Finbold

PaxMedica to Present at the Jan 26th Virtual Investor Summit Microcap Event

Presentation on Thursday, January 26th, 2023 at 1:30 PM EST

2 weeks ago - GlobeNewsWire

PaxMedica, Inc. Launches Updated Corporate Website at PaxMedica.com

Update Offers More Comprehensive Understanding of PaxMedica's Focus, Process and Progress

1 month ago - GlobeNewsWire

PaxMedica to Present at the Benchmark Company's Upcoming Discovery One-on-One Investor Conference

TARRYTOWN, NY, Nov. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug...

2 months ago - GlobeNewsWire

PXMD, GETY: The Top 5 Short Squeeze Stocks to Watch This Week

We're checking in on the top short squeeze stocks to watch this week as traders continue to have an interest in this part of the market! Short squeeze stocks are often subject to volatility with massi...

Other symbols: ABEOGETYHOURSURG
2 months ago - InvestorPlace

Why Is PaxMedica (PXMD) Stock Up 51% Today?

PaxMedica (NASDAQ: PXMD) stock is taking off on Friday after the biopharmaceutical company entered into an investment agreement with Lincoln Park Capital Fund. According to a press release, this cove...

2 months ago - InvestorPlace

PaxMedica, Inc. Enters Into Committed Equity Investment Agreement for up to $20 Million With Lincoln Park Capital

-Agreement Provides Flexible Funding on Path to NDA Submission for PAX-101-

2 months ago - GlobeNewsWire

PaxMedica, Inc. Provides Business Update and Reports Third Quarter 2022 Financial Results

-PXMD Strengthened Executive Team and Board of Directors With Recent Appointments After IPO in August 2022-

3 months ago - GlobeNewsWire

PaxMedica Initiates Clinical Program to Advance PAX-101 Towards FDA Submission

Final Study Results are Expected in First Half of 2023

3 months ago - GlobeNewsWire

A Major Squeeze Is Brewing in PaxMedica (PXMD) Stock

PaxMedica (NASDAQ: PXMD) stock could be preparing for a short squeeze with recent signs showing potential for it to surge in price. Let's start off with the basics, which include the company completi...

3 months ago - InvestorPlace

PaxMedica Appoints Stefan Schwabe MD, PhD as Chief Medical Officer

Dr. Schwabe brings 30+ years of Clinical Experience in the Pharmaceutical Industry

3 months ago - GlobeNewsWire

PaxMedica Appoints Specialty Pharma Industry Leader Charles J. Casamento to Its Board of Directors

Founder of several public life sciences companies including Questcor, Osteologix and Indevus, Casamento will serve as an Independent Director

4 months ago - GlobeNewsWire

PaxMedica, Inc. Provides Corporate Update After IPO

-PXMD Strengthened Executive Team with Recent Appointment of Stephen D. Sheldon As Chief Financial Officer-

4 months ago - GlobeNewsWire

Why Are Shipping Stocks Down Today?

Source: Darryl Brooks / Shutterstock.com Shipping stocks are sinking on Friday as reports come in that U.S. ports are still having trouble following turbulence during the pandemic. Shipping companies ...

Other symbols: BBBYEGLEGOGLKSSZIM
5 months ago - InvestorPlace

Is PaxMedica (PXMD) Stock the Next Hot IPO?

IPO season continues today with another exciting entrant. PaxMedica (NASDAQ: PXMD) is the newest company to make its public debut.

5 months ago - InvestorPlace

Craft Capital Management Announces Pricing of Initial Public Offering for PaxMedica, Inc.

Shares will Trade on Nasdaq Capital Market under Ticker Symbol "PXMD" TARRYTOWN, NY / ACCESSWIRE / August 26, 2022 / PaxMedica, Inc. (Nasdaq:PXMD), a clinical stage biopharmaceutical company focusing ...

5 months ago - Accesswire

PaxMedica, Inc. Announces Pricing of Initial Public Offering

Shares will Trade on Nasdaq Capital Market under Ticker Symbol “PXMD”

5 months ago - GlobeNewsWire